Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
The Nasdaq recorded its fifth straight day of losses on Friday, while the S&P 500 ended marginally lower, with AI-related chip stocks taking a hit, as investors rotated out of major tech stocks and took refuge in defensive assets.
LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Eli Lilly and Company (NYSE:LLY) is one of the Stocks That Will Make You Rich Over the Next 3 Years. Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over the past 30 days, and the Street expects more than 13.6% upside from the current level. Recently, on June 25, Leerink analyst David Risinger raised […]
Eli Lilly and Company (NYSE:LLY) is among the Best Healthcare Stocks Stocks. On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027. Executive Vice President Patrik Jonsson said the company will start targeting patients paying […]
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. Management […]
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price target on the stock to $1,232 from $1,119 and maintained an Outperform rating on the shares. In a separate development, […]
Eli Lilly's cancer drug Jaypirca received a positive opinion from the European Medicines Agency regarding its use in chronic lymphocytic leukemia. The opinion supports potential use of Jaypirca across all lines of therapy for CLL in Europe. The recommendation is based on Phase 3 clinical trial data and now moves to European Commission review. Eli Lilly (NYSE:LLY) is best known recently for its GLP-1 portfolio, and oncology remains an important part of the business. The EMA's positive view...
Eli Lilly and EZ Corp. lead stocks to watch near buy points this week as investors seek shelter in defensive growth names. The relative strength lines of all top five stocks near buy points are making new highs or near highs. The strong RS lines, which track performance vs. the S&P 500, are especially bullish given the overall uncertain stock market.
Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL […]
The pharma titan is expanding into new markets.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's committee for human medicines backed its cancer drug, Jaypirca, and the company's popular weight-loss treatments were set for inclusion in a new Medicare program.
Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and
The smartphone could be a thing of the past if Snap has its way. But at $2,195, it could be a tall order to sell Specs to consumers, even if they were stylish.
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.
Trump’s children have been buying and selling stock on his behalf while he’s in office, posing a legal quagmire.
Eli Lilly and Co (NYSE:LLY) shares climbed nearly 6% on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The...
In June 2026, Eli Lilly’s Lilly TuneLab announced a collaboration under which Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-enabled biotech companies using the TuneLab drug discovery platform. This collaboration ties Charles River more closely into Lilly’s Catalyze360 ecosystem, potentially deepening its role in data-rich, AI-enhanced preclinical research workflows. We’ll now examine how Charles River’s deeper integration into Lilly’s AI-driven...
US stocks are set for another difficult session on Friday, with the Nasdaq on course for a fifth straight day of losses as investors continue to rotate out of technology shares ahead of the quarter-end. Nasdaq futures were down 1.2% ahead of the opening bell, while S&P 500 and Dow Jones...
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
